Seems like CC is shameless but very determined. I wonder what her motives are? Is she paid by SNY? Has she no integrity? Anyway, it seems that the SA article had a positive effect on PLX share price!
Hello Spideyboy! I appreciate your efforts in terms of discussion with this cc scammer. I gave up these attempts a long time ago because I think they are counterproductive.At first I tried to argue but quickly understood her articles were not supported by any arguments and contained deliberately false statements. This is a kind of prostitution IMO. I wrote to her about it in her SA Inbox. If she writes these articles for free, then she obviously has mental problems.I don't feel comfortable telling a woman she's crazy. I think it's better to be a prostitute than crazy. When I hear her name I often recall the painting by M.Caravaggio "The Cardsharps". I don't understand why so many people pay attention to what she writes. Look at her terrible profile C. C. Abbott Seeking Alpha Financial Blogger Ranked #8,311 out of 8,370 Bloggers on TipRanks (#16,130 out of 16,309 overall experts)
I think she has the same relationship with the University of Oxford as I have with conducting a symphony orchestra. There are two main questions for me today: 1. OK from the FDA and EMA, 2. follow-up sales.
Could you answer please the following question for me. I always thought that Fabrazyme and Replagal are two drugs that are close in terms of effectiveness, but compared to Replagal, PRX-102 looks like superior, and compared to Fabrazyme, only demonstrates non-inferiority.??
About 3 months ago I read the research that interviewed several professionals. They believed that the FDA clearance for PRX-102 was imminent and the superiority PRX-102 to Fabrazyme was questioned because the dose in BALANCE trial was the same- 1 mg/kg and Replagal's dose 0.2 mg/kg. While they believed that superiority PRX-102 to Fabrazyme is possible,but it can be achieved in ~8-10 years after the start of PRX-102 use.
News 
Market Data 
Discover 
